Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Partnerships Provide Global Foundation For Alvotech

Network Of Deals Gives Company’s Biosimilar Portfolio Worldwide Reach

Executive Summary

A network of marketing deals with key players across the globe has laid the foundations for Alvotech’s biosimilars to be marketed worldwide, the company’s founder and chairman tells Generics Bulletin in an exclusive interview.

You may also be interested in...



Coherus Gets Goal Date On US Adalimumab Biosimilar

A further FDA approval for a biosimilar to Humira could be on the cards, after Coherus revealed the agency’s goal date for its CHS-1420 adalimumab application.

Alvotech’s Iceland Expansion Will Double Capacity

As Alvotech advances towards launches around the world for its portfolio of biosimilars, the firm is ramping up capacity at its Reykjavik facility.

Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy

Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel